<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Campana, Raffaela</dc:creator>
  <dc:creator>Moritz, Katharina</dc:creator>
  <dc:creator>Neubauer, Angela</dc:creator>
  <dc:creator>Huber, Hans</dc:creator>
  <dc:creator>Henning, Rainer</dc:creator>
  <dc:creator>Brodie, Tess M.</dc:creator>
  <dc:creator>Kaider, Alexandra</dc:creator>
  <dc:creator>Sallusto, Federica</dc:creator>
  <dc:creator>Wöhrl, Stefan</dc:creator>
  <dc:creator>Valenta, Rudolf</dc:creator>
  <dc:date>2017-09-14</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">The effects of epicutaneous allergen administration on systemic immune responses in allergic  and non-allergic individuals has not been investigated with defined allergen molecules. We  studied the effects of epicutaneous administration of rBet v 1 and rBet v 1 fragments on systemic  immune responses in allergic and non-allergic subjects. We conducted a clinical trial in which  rBet v 1 and two hypoallergenic rBet v 1 fragments were applied epicutaneously by atopy patch  testing (APT) to 15 birch pollen (bp) allergic patients suffering from atopic dermatitis, 5 bp-allergic  patients suffering from rhinoconjunctivitis only, 5 patients with respiratory allergy without bp  allergy and 5 non-allergic individuals. Epicutaneous administration of rBet v 1 and rBet v 1  fragments led to strong and significant increases of allergen-specific T cell proliferation (CLA+  and CCR4+T cell responses) only in bp-allergic patients with a positive APT reaction. There were  no relevant changes of Bet v 1-specific IgE and IgG responses. No changes were noted in  allergic subjects without bp allergy and in non-allergic subjects. Epicutaneous allergen  application boosts specific T cell but not antibody responses mainly in allergic, APT-positive  patients suggesting IgE-facilitated allergen presentation as mechanism for its effects on systemic  allergen-specific immune responses.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://susi.usi.ch/global/documents/319148</dc:identifier>
  <dc:identifier>https://localhost:5000/ark:/12658/srd1319148</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/319148/files/Campana_SR_2017.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-017-10278-1</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1319148</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>Scientific reports. - 2017, vol. 7, p. 11657</dc:source>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
